Carregant...

Identification of a New Heterocyclic Scaffold for Inhibitors of the Polo-Box Domain of Polo-like Kinase 1

As a mitotic-specific target widely deregulated in various human cancers, polo-like kinase 1 (Plk1) has been extensively explored for anticancer activity and drug discovery. Although multiple catalytic domain inhibitors were tested in preclinical and clinical studies, their efficacies are limited by...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Med Chem
Autors principals: Alverez, Celeste N., Park, Jung-Eun, Toti, Kiran S., Xia, Yangliu, Krausz, Kristopher W., Rai, Ganesha, Bang, Jeong K., Gonzalez, Frank J., Jacobson, Kenneth A., Lee, Kyung S.
Format: Artigo
Idioma:Inglês
Publicat: 2020
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7769008/
https://ncbi.nlm.nih.gov/pubmed/33175530
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acs.jmedchem.0c01669
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!